Matches in Wikidata for { <http://www.wikidata.org/entity/Q66394541> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q66394541 description "clinical trial" @default.
- Q66394541 description "ensayu clínicu" @default.
- Q66394541 description "klinisch onderzoek" @default.
- Q66394541 description "клінічне випробування" @default.
- Q66394541 description "կլինիկական փորձարկում" @default.
- Q66394541 name "Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma" @default.
- Q66394541 name "Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma" @default.
- Q66394541 type Item @default.
- Q66394541 label "Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma" @default.
- Q66394541 label "Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma" @default.
- Q66394541 prefLabel "Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma" @default.
- Q66394541 prefLabel "Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma" @default.
- Q66394541 P1050 Q66394541-C11AEE3E-12BB-4E02-B297-56A7A80F5A51 @default.
- Q66394541 P1132 Q66394541-7598BA08-41E2-4460-83CF-597D8EEF9985 @default.
- Q66394541 P1476 Q66394541-8C009E68-1EB0-45C9-9483-453224EB0380 @default.
- Q66394541 P17 Q66394541-252E813C-4EAF-42A8-998F-476F917D1922 @default.
- Q66394541 P17 Q66394541-735C8800-6E2D-4694-A2E8-014845A65793 @default.
- Q66394541 P17 Q66394541-79519764-E8CB-482C-8799-7430FDDE9BCB @default.
- Q66394541 P17 Q66394541-7E611EB9-6AD0-498E-82E5-A9A8D06E6961 @default.
- Q66394541 P17 Q66394541-D3316ABE-7164-4670-A4BE-5C691D959A37 @default.
- Q66394541 P2899 Q66394541-9BE900A6-C6AF-4CAE-A303-1CEEFA8B2FB9 @default.
- Q66394541 P3098 Q66394541-44D1811D-FD14-424E-BB26-6758B9FA6862 @default.
- Q66394541 P31 Q66394541-7CFC0D82-70B9-4F40-8A40-DF04110191D4 @default.
- Q66394541 P4844 Q66394541-052DCC8A-2F83-4B46-A28A-7638FD633CC9 @default.
- Q66394541 P580 Q66394541-7A8026D8-87AE-4FBF-856C-ECDBE1F29A4D @default.
- Q66394541 P582 Q66394541-3D11B589-061A-4DD9-8916-05CF051F49EC @default.
- Q66394541 P6099 Q66394541-52E364F2-33A8-4EA6-B624-6698EF334572 @default.
- Q66394541 P8363 Q66394541-B70816E9-A07A-4C21-A764-5CE5A3BCF94B @default.
- Q66394541 P1050 Q467635 @default.
- Q66394541 P1132 "+125" @default.
- Q66394541 P1476 "An Open-label Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma" @default.
- Q66394541 P17 Q183 @default.
- Q66394541 P17 Q29 @default.
- Q66394541 P17 Q38 @default.
- Q66394541 P17 Q41 @default.
- Q66394541 P17 Q43 @default.
- Q66394541 P2899 "+18" @default.
- Q66394541 P3098 "NCT02902965" @default.
- Q66394541 P31 Q30612 @default.
- Q66394541 P4844 Q408524 @default.
- Q66394541 P580 "2016-09-30T00:00:00Z" @default.
- Q66394541 P582 "2018-10-26T00:00:00Z" @default.
- Q66394541 P6099 Q42824440 @default.
- Q66394541 P8363 Q78089383 @default.